The Effects of Danggui-Shaoyao-San on Neuronal Degeneration and Amyloidosis in Mouse and Its Molecular Mechanism for the Treatment of Alzheimer's Disease.

Cong Yang,You-Sheng Mo,Hui-Fang Chen,Yan-Hui Huang,Shao-Ling Li,Hong Wang,Shui-Qing Huang,Xiang Chang,Qun Du,Qi Wang
DOI: https://doi.org/10.31083/j.jin2002025
2021-01-01
Journal of Integrative Neuroscience
Abstract:The abnormal deposition of the extracellular amyloid-β peptide is the typical pathological hallmark of Alzheimer's disease. Strategies to reduce the amyloid-β deposition effectively alleviate the neuronal degeneration and cognitive deficits of Alzheimer's disease. Danggui-Shaoyao-San has been considered a useful therapeutic agent known for the treatment of Alzheimer's disease. However, the mechanism of Danggui-Shaoyao-San for the treatment of Alzheimer's disease remains unclear. We investigated Danggui-Shaoyao-San's effect on amyloidosis and neuronal degeneration in an APP/PS1 mouse model. We found Danggui-Shaoyao-San alleviated the cognitive deficits in APP/PS1 mice. Additionally, Danggui-Shaoyao-San ameliorated the neuronal degeneration in these mice. Danggui-Shaoyao-San reduced the amyloidosis and amyloid-β1-42 deposition in APP/PS1 mouse brain and down-regulated the receptor for advanced glycation end products, and up-regulated the level of low-density lipoprotein receptor-related protein-1. However, the protein expression of the β-amyloid precursor protein, β-Secretase and presenilin-1 (PS1) in the amyloid-β production pathway, and the expression of neprilysin and insulin-degrading enzyme in the amyloid-β degradation pathway were not altered. Our findings collectively suggest that Danggui-Shaoyao-San could ameliorate the amyloidosis and neuronal degeneration of Alzheimer's disease, which may be associated with its up-regulation lipoprotein receptor-related protein-1 and down-regulation of the receptor for advanced glycation end products.
What problem does this paper attempt to address?